Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 6.6b

Immunosuppression Use for Induction by Discharge Regimen, 2005 to 2009

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Discharge Regimen (w/ or w/o Steroids Use) All
CyA Tac CyA+ MMF Tac+ MMF Tac+ Aza Siro+ MMF CyA+ Siro Tac+ Siro Other
Functioning Graft with Immunosuppression Info at Discharge 1 276 5 426 2 3 3 56 109 881
% of All Regimens 0.1% 31.3% 0.6% 48.4% 0.2% 0.3% 0.3% 6.4% 12.4% 100.0%
Induction Drug 0.0% 0.4% 0.0% 1.6% 0.0% 0.0% 0.0% 0.0% 0.9% 1.0%
Atgam/NRATG/NRATS
OKT3 0.0% 6.2% 0.0% 8.7% 0.0% 0.0% 0.0% 5.4% 7.3% 7.4%
Thymoglobulin 0.0% 13.4% 100.0% 63.4% 0.0% 33.3% 100.0% 17.9% 121.1% 52.0%
Zenapax 0.0% 12.0% 20.0% 3.8% 0.0% 0.0% 0.0% 5.4% 8.3% 7.0%
Simulect 100.0% 0.7% 0.0% 5.4% 0.0% 0.0% 0.0% 0.0% 5.5% 3.6%
Campath 0.0% 25.4% 0.0% 15.0% 50.0% 33.3% 0.0% 35.7% 22.0% 20.4%
No Induction Drugs Recorded 0.0% 48.2% 0.0% 13.4% 50.0% 33.3% 0.0% 42.9% 11.0% 25.9%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.